Stock Fundamentals

Company Information

Company Name
Amphastar P
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US03209R1032
CIK: 0001297184
CUSIP: 03209R103
Currency: USD
Full Time Employees: 1,976
Phone: 909 980 9484
Fiscal Year End: December
IPO Date: Jun 25, 2014
Description:

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Address:

11570 6th Street, Rancho Cucamonga, CA, United States, 91730

Directors & Officers

Name Title Year Born
Dr. Ziping Luo Ph.D. Chairman of the Board, Chief Scientist & COO 1950
Dr. Yongfeng Zhang Ph.D. Co-Founder, President, CEO, Chief Scientific Officer & Director 1947
Mr. William J. Peters M.B.A. CFO, Executive VP of Finance, Treasurer & Director 1968
Mr. Jacob Liawatidewi M.B.A. Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director 1974
Mr. Rong Zhou M.S. Senior EVP of Production & EVP of Scientific Affairs 1959
Mr. Dan Dischner M.B.A. Senior Vice President of Human Resources & Corporate Communication NA
Tony Marrs M.B.A., M.P.H., M.S. Executive VP of Regulatory Affairs & Clinical Operations NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 17, 2025 Rong Zhou N/A Sale 9.79K $26.20 $256.42K
Dec 12, 2025 Floyd F Petersen N/A Sale 2.43K $25.92 $62.88K
Dec 11, 2025 Floyd F Petersen N/A Sale 1.74K $25.69 $44.62K
Nov 25, 2025 Richard K Prins N/A Sale 4.18K $27.10 $113.25K
Nov 13, 2025 Floyd F Petersen N/A Sale 16.68K $26.49 $441.83K
Nov 03, 2025 Floyd F Petersen N/A Sale 500.00 $25.27 $12.64K
Oct 01, 2025 Floyd F Petersen N/A Sale 500.00 $27.20 $13.60K
Aug 01, 2025 Floyd F Petersen N/A Sale 500.00 $20.83 $10.42K
Jul 02, 2025 Floyd F Petersen N/A Sale 500.00 $23.47 $11.74K
Jun 02, 2025 Floyd F Petersen N/A Sale 500.00 $25.67 $12.84K
May 01, 2025 Floyd F Petersen N/A Sale 500.00 $24.08 $12.04K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 5.42M Mar 31, 2026 12.30% $0.00 -0.74%
Vanguard Group Inc 2.61M Dec 31, 2025 5.92% $0.00 -0.87%
Dimensional Fund Advisors, Inc. 2.03M Mar 31, 2026 4.60% $0.01 12.68%
State Street Corp 1.61M Mar 31, 2026 3.65% $0.00 4.94%
Vanguard Capital Management, LLC 1.54M Mar 31, 2026 3.50% $0.00 0.00%
TD Asset Management Inc 1.54M Mar 31, 2026 3.50% $0.02 -21.50%
Fuller & Thaler Asset Management Inc 1.40M Mar 31, 2026 3.16% $0.09 -49.98%
Marshall Wace Asset Management Ltd 1.03M Mar 31, 2026 2.33% $0.02 -17.11%
American Century Companies Inc 1.02M Mar 31, 2026 2.31% $0.01 52.94%
Geode Capital Management, LLC 976.65K Mar 31, 2026 2.22% $0.00 10.13%
BTIM Corp 944.79K Mar 31, 2026 2.14% $0.15 -13.10%
TD Global Investment Solutions – TD Epoch 898.90K Mar 31, 2026 2.04% $0.11 -20.21%
Vanguard Portfolio Management, LLC 787.82K Mar 31, 2026 1.79% $0.00 0.00%
D. E. Shaw & Co LP 665.54K Mar 31, 2026 1.51% $0.01 19.47%
LSV Asset Management 651.71K Mar 31, 2026 1.48% $0.03 490.86%
Amvescap Plc. 604.77K Mar 31, 2026 1.37% $0.00 20.62%
Renaissance Technologies Corp 553.90K Mar 31, 2026 1.26% $0.02 1.69%
Systematic Financial Management LP 452.90K Mar 31, 2026 1.03% $0.20 3.98%
Morgan Stanley - Brokerage Accounts 420.34K Mar 31, 2026 0.95% $0.00 -28.95%
UBS Group AG 420.26K Mar 31, 2026 0.95% $0.00 63.77%

Shares Statistics

Shares Outstanding: 44.09M
Shares Float: 32.82M
% Insiders: 2,974.20%
% Institutions: 7,638.20%
Short % Float: 17.78%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 2.15M 4.86% ▲ 0.04% May 29, 2026
2 FullerThaler Behavioral Sm-Cp Eq R6 1.43M 3.24% ▲ 6.89% Apr 30, 2026
3 FullerThaler Behavioral Small-Cap Equity 1.34M 3.03% ▲ 3.62% Dec 31, 2025
4 FullerThaler Beh Small-Cap Equity SMA 1.34M 3.03% ▲ 0.00% Dec 31, 2025
5 Vanguard Total Stock Mkt Idx Inv 1.11M 2.52% ▲ 0.00% Apr 30, 2026
6 TD U.S. Capital Reinvestment I 981.53K 2.23% ▼ 4.98% Dec 31, 2025
7 Avantis US Small Cap Value ETF 945.54K 2.14% ▲ 0.10% May 30, 2026
8 iShares Russell 2000 ETF 863.49K 1.96% ▲ 0.93% May 29, 2026
9 TD Epoch U.S. Quality Capital Reinvestmt 770.52K 1.75% ▼ 21.50% Mar 31, 2026
10 DFA US Small Cap Value I 460.40K 1.04% ▲ 12.14% Apr 30, 2026

Valuation Metrics

Enterprise Value: $1.28B
Trailing P/E: 12.10
Forward P/E: 0.00

Financial Highlights

Market Cap: $885.83M
EBITDA: $197.27M
P/E Ratio: $12.10
PEG Ratio: $2.77
Book Value: $17.33
Earnings/Share: $1.66
Profit Margin: 11.00%
Operating Margin: 7.96%
ROA (TTM): 5.34%
ROE (TTM): 10.39%
Revenue (TTM): $720.53M
Revenue/Share (TTM): $15.61
Earnings Growth (YOY): -72.50%
Revenue Growth (YOY): 0.40%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 4.02x 0.78x 0.52x 5.51x 2.91x
2024-12-31 3.07x 0.83x 0.54x 6.77x 2.19x
2023-12-31 2.17x 0.93x 0.58x 7.25x 2.47x
2022-12-31 3.99x 0.15x 0.29x 58.23x 0.54x
2021-12-31 3.06x 0.18x 0.34x 78.97x 0.72x
2020-12-31 2.49x 0.12x 0.29x 29.29x 1.65x
2019-12-31 2.84x 0.13x 0.27x -0.33x 2.39x
2018-12-31 2.06x 0.15x 0.29x -35.49x 6.36x
2017-12-31 2.79x 0.14x 0.26x -1.08x 3.96x
2016-12-31 3.04x 0.11x 0.23x 15.32x 1.25x
2015-12-31 2.93x 0.14x 0.24x -6.99x 10.61x
2014-12-31 3.16x 0.16x 0.28x -29.53x -14.14x
2013-12-31 2.64x 0.13x 0.26x 18.26x 1.05x
2012-12-31 2.76x 0.16x 0.26x 32.39x 1.00x
2011-12-31 N/A N/A N/A -57.44x 0.00x
2010-12-31 N/A N/A N/A N/A N/A

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about AMPH.US!